FDA
-
-
-
-
-
-
-
Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization
-
-
-
-
-
-
-
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
-
-
-
-
-
-
-
FDA grants orphan drug designation to Quoin's QRX003 for Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
-
325,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

